Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virginia ECs

This article was originally published in The Tan Sheet

Executive Summary

Bill allowing OTC access to emergency contraceptives remains in contention as state conferees work to reach agreement on status of parental consent amendment added in House but removed by Senate committee. Virginia's legislative session was scheduled to end Feb. 24, and conferees had yet to meet as of Feb. 23. HB 2782 passed the House Feb. 1 (1"The Tan Sheet" Feb. 5, p. 13). It now appears parental consent clause, which advocates say weakens bill, will come down to close vote in Republican-controlled legislature

You may also be interested in...



Emergency Contraceptive Bill Passes Virginia House, Faces Senate Fight

A key amendment to legislation that would make emergency contraceptives available "behind-the-counter" in Virginia could limit the scope of the original bill, which cleared the House of Delegates Feb. 1.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS092243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel